Several Indian companies, including Larsen & Toubro, Godrej Consumer Products, and Dr Reddy’s Laboratories, are expected to record double-digit growth in their topline and bottomline figures for the March quarter due to healthy execution and strong order books. L&T’s core engineering business is expected to drive the topline with a healthy opening order book. Meanwhile, Revlimid, the cancer drug, is expected to have contributed significantly to growth in Dr Reddy’s US sales.
Asian stocks tread water at the start of Fed week
Asian stocks opened cautiously as traders assessed strained China-Japan relations and upcoming central bank decisions. Investor caution grew regarding the AI rally’s sustainability, with markets